Open AccessJournal Article
Chronotherapeutic oral drug absorption system verapamil is effective in reducing morning blood pressure in African Americans: a post hoc analysis of the chrono trial.
Reads0
Chats0
TLDR
A post hoc analysis of data from the community-based CHRONO trial was undertaken to assess racial/ethnic differences in the safety and efficacy of the Chronotherapeutic Oral Drug Absorption System (CODAS) formulation of verapamil in a real-world setting.Abstract:
Results of several clinical trials have shown that verapamil is effective in reducing blood pressure (BP) in African Americans, a population at high risk for hypertension and target-organ damage. Nonetheless, adequate control of BP is perceived as difficult to achieve in this population. A post hoc analysis of data from the community-based CHRONO trial (Controlling Hypertension in the moRning with a ChrONO medication) was undertaken to assess racial/ethnic differences in the safety and efficacy of the Chronotherapeutic Oral Drug Absorption System (CODAS) formulation of verapamil in a real-world setting. Once-daily administration of the CODAS formulation of verapamil significantly reduced morning BP (P or =10% reduction from baseline) and diastolic BP ( or =10 mmHg from baseline) combined was 70.8%, and 60% of those individuals responded at the lowest (200 mg) dose. Of the 59.7% of African Americans who reached the target BP of <140/90 mmHg, 64% did so at the 200-mg dose. Response rates were not affected by gender, age or treatment history, and CODAS-verapamil was well tolerated in all ethnic/racial treatment groups. In a trial conducted in actual clinical practices, the CODAS formulation of verapamil was shown to be safe and effective in African Americans, Caucasians, Hispanics and Asians.read more
Citations
More filters
Journal ArticleDOI
Epidemiology and management of hypertension in the hispanic population: A review of the available literature
TL;DR: This article discusses ethnic differences in hypertension and cardiovascular risk factors and reviews the literature on the efficacy of antihypertensive agents in Hispanic patients, with a focus on the role of renin-angiotensinaldosterone system (RAAS) inhibition in the management of hypertension in these patients.
References
More filters
Journal ArticleDOI
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
Aram V. Chobanian,George L. Bakris,Henry R. Black,William C. Cushman,Lee A. Green,Joseph L. Izzo,Daniel W. Jones,Barry J. Materson,Suzanne Oparil,Jackson T. Wright,Edward J. Roccella +10 more
TL;DR: The most effective therapy prescribed by the most careful clinician will control hypertension only if patients are motivated, and empathy builds trust and is a potent motivator.
Journal ArticleDOI
A Calcium Antagonist vs a Non-Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial
Carl J. Pepine,Eileen M. Handberg,Rhonda M. Cooper-DeHoff,Ronald G. Marks,Peter R. Kowey,Franz H. Messerli,Giuseppe Mancia,Jose L. Cangiano,David Garcia-Barreto,Matyas Keltai,Serap Erdine,Heather A. Bristol,H Robert Kolb,George L. Bakris,Jerome D. Cohen,William W. Parmley +15 more
TL;DR: The verapamil-trandolapril- based strategy was as clinically effective as the atenolol-hydrochlorothiazide-based strategy in hypertensive CAD patients, and was also recommended for patients with heart failure, diabetes, or renal impairment.
Journal ArticleDOI
Management of High Blood Pressure in African Americans: Consensus Statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks
Janice G. Douglas,George L. Bakris,Murray Epstein,Keith C. Ferdinand,Carlos M. Ferrario,John M. Flack,Kenneth Jamerson,Wendell E. Jones,Julian Haywood,Randall Maxey,Elizabeth Ofili,Elijah Saunders,Ernesto L. Schiffrin,Domenic A. Sica,James R. Sowers,Donald G. Vidt +15 more
TL;DR: The purpose of this consensus statement is to offer primary care providers a practical, evidence-based clinical tool for achieving blood pressure goals in African American patients.
Journal ArticleDOI
A Comparison of the Efficacy and Safety of a β-Blocker, a Calcium Channel Blocker, and a Converting Enzyme Inhibitor in Hypertensive Blacks
Elijah Saunders,Matthew R. Weir,B. Wayne Kong,John W. Hollifield,James Gray,Victor Vertes,James R. Sowers,Michael B. Zemel,Charles L. Curry,James A. Schoenberger,Jackson T. Wright,Walter M. Kirkendall,Edward C. Conradi,Patricia Jenkins,Barry McLean,Barry M. Massie,Gerald S. Berenson,Walter Flamenbaum +17 more
TL;DR: Atenolol, captopril, and verapamil sustained release therapy was associated with goal blood pressure achievement during the first treatment period and during the second treatment period, and side effects were minimal and comparable for all three drugs.
Journal ArticleDOI
Effect of Calcium Channel or β-Blockade on the Progression of Diabetic Nephropathy in African Americans
TL;DR: The concept that antihypertensive agents that persistently maintain reductions in both arterial pressure and proteinuria slow the progression of diabetic renal disease in African Americans to a greater extent than those agents without these effects is supported.